Identifying immune-related predictive factors for post-eribulin therapy in patients with HER2-negative advanced breast cancer- a multicenter retrospective study

Key Points

• Post-eribulin therapy shows promising outcomes based on specific immune-related predictive factors in HER2-negative advanced breast cancer patients.
• The study reports a significant correlation between immune profiles and response rates to eribulin, with notable variations in treatment effectiveness.
• Retrospective study conducted across multiple centers evaluates data from various patients with advanced breast cancer receiving eribulin.
• Findings support the potential for personalized treatment approaches by integrating immune-based strategies in advanced breast cancer management.